Clinical Pharmacology Insights that Accelerate Drug Development

臨床薬理は医薬品添付文書の 50% 以上の記載を占めています。そのため、開発品の安全性と有効性をいかに最適化するかを理解することこそが、お客様の開発計画の成功にとって極めて重要と言えます。Are you feeling daunted by the task of planning your drug’s clinical development? Well, you’ve certainly come to the right place. In Raj’s Corner, we’ve assembled a series of expert blog posts that will explain clinical pharmacology best practices that support the most streamlined and informative clinical development program. Dr. Rajesh Krishna is currently a Senior Director at Certara’s Integrated Drug Development group. He has more than 20 years of drug development experience with past leadership roles in product value enhancement and quantitative clinical pharmacology at Merck, Aventis, and Bristol-Myers Squibb.
rajesh krishna (1)

Rajesh Krishna

Rajesh Krishna, PhD is a Senior Director in Integrated Drug Development at Certara Strategic Consulting. Merck、Sanofi (旧 Aventis)、Bristol Myers Squibb における、20 年以上にわたるトランスレーショナルサイエンスや臨床開発の経験を経てサターラに入社しました。彼は 40 以上の治験薬、200 以上の第 1/1b 相試験、および世界各地における 9 の新規化合物の登録に貢献してきました。


Powered by GlobalLink OneLink Software